137 related articles for article (PubMed ID: 26395519)
1. Evaluation of the new LIAISON(®) CMV IgG, IgM and IgG Avidity II assays.
Delforge ML; Desomberg L; Montesinos I
J Clin Virol; 2015 Nov; 72():42-5. PubMed ID: 26395519
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the LIAISON(®) CMV IgG Avidity II and the VIDAS(®) CMV IgG Avidity II assays for the diagnosis of primary infection in pregnant women.
Sellier Y; Guilleminot T; Ville Y; Leruez-Ville M
J Clin Virol; 2015 Nov; 72():46-8. PubMed ID: 26397203
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the LIAISON®XL and ARCHITECT IgG, IgM, and IgG avidity assays for the diagnosis of Toxoplasma, cytomegalovirus, and rubella virus infections.
Genco F; Sarasini A; Parea M; Prestia M; Scudeller L; Meroni V
New Microbiol; 2019 Apr; 42(2):88-93. PubMed ID: 30994178
[TBL] [Abstract][Full Text] [Related]
4. Re-evaluation of the VIDAS(®) cytomegalovirus (CMV) IgG avidity assay: determination of new cut-off values based on the study of kinetics of CMV-IgG maturation.
Vauloup-Fellous C; Berth M; Heskia F; Dugua JM; Grangeot-Keros L
J Clin Virol; 2013 Feb; 56(2):118-23. PubMed ID: 23182774
[TBL] [Abstract][Full Text] [Related]
5. Improvement of cytomegalovirus avidity testing by adjusting the concentration of CMV-specific IgG in test samples.
Dangel V; Bäder U; Enders G
J Clin Virol; 2006 Mar; 35(3):303-9. PubMed ID: 16298547
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two serological screening strategies for cytomegalovirus primary infection in the first trimester of pregnancy.
Fourgeaud J; Nguyen CÂ; Guilleminot T; Ville Y; Leruez-Ville M
J Clin Virol; 2023 Dec; 169():105614. PubMed ID: 37982548
[TBL] [Abstract][Full Text] [Related]
7. Validation of an in-house assay for cytomegalovirus immunoglobulin G (CMV IgG) avidity and relationship of avidity to CMV IgM levels.
Prince HE; Leber AL
Clin Diagn Lab Immunol; 2002 Jul; 9(4):824-7. PubMed ID: 12093680
[TBL] [Abstract][Full Text] [Related]
8. The role of IgG avidity in diagnosis of cytomegalovirus infection in newborns and infants.
Vilibić-Cavlek T; Ljubin-Sternak S; Vojnović G; Sviben M; Mlinarić-Galinović G
Coll Antropol; 2012 Mar; 36(1):297-300. PubMed ID: 22816235
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the new architect cytomegalovirus immunoglobulin M (IgM), IgG, and IgG avidity assays.
Lagrou K; Bodeus M; Van Ranst M; Goubau P
J Clin Microbiol; 2009 Jun; 47(6):1695-9. PubMed ID: 19339470
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the indirect and IgM-capture anti-human cytomegalovirus IgM ELISA methods as confirmed by cytomegalovirus IgG avidity.
Ikuta K; Koshizuka T; Kanno R; Inoue N; Kubo T; Koyano S; Suzutani T
Microbiol Immunol; 2019 May; 63(5):172-178. PubMed ID: 31012489
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of the new Roche platform of serological and molecular cytomegalovirus-specific assays in the diagnosis and prognosis of congenital cytomegalovirus infection.
Chiereghin A; Pavia C; Gabrielli L; Piccirilli G; Squarzoni D; Turello G; Gibertoni D; Simonazzi G; Capretti MG; Lanari M; Lazzarotto T
J Virol Methods; 2017 Oct; 248():250-254. PubMed ID: 28801056
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Abbott AxSYM cytomegalovirus (CMV) immunoglobulin M (IgM) assay in conjunction with other CMV IgM tests and a CMV IgG avidity assay.
Lazzarotto T; Galli C; Pulvirenti R; Rescaldani R; Vezzo R; La Gioia A; Martinelli C; La Rocca S; Agresti G; Grillner L; Nordin M; van Ranst M; Combs B; Maine GT; Landini MP
Clin Diagn Lab Immunol; 2001 Jan; 8(1):196-8. PubMed ID: 11139220
[TBL] [Abstract][Full Text] [Related]
13. Potential impact of different cytomegalovirus (CMV) IgM assays on an algorithm requiring IgM reactivity as a criterion for measuring CMV IgG avidity.
Prince HE; Lapé-Nixon M; Brenner A; Pitstick N; Couturier MR
Clin Vaccine Immunol; 2014 Jun; 21(6):813-6. PubMed ID: 24671558
[TBL] [Abstract][Full Text] [Related]
14. National prevalence estimates for cytomegalovirus IgM and IgG avidity and association between high IgM antibody titer and low IgG avidity.
Dollard SC; Staras SA; Amin MM; Schmid DS; Cannon MJ
Clin Vaccine Immunol; 2011 Nov; 18(11):1895-9. PubMed ID: 21918114
[TBL] [Abstract][Full Text] [Related]
15. The value of CMV IgG avidity and immunoblot for timing the onset of primary CMV infection in pregnancy.
Enders G; Daiminger A; Bäder U; Exler S; Schimpf Y; Enders M
J Clin Virol; 2013 Feb; 56(2):102-7. PubMed ID: 23153820
[TBL] [Abstract][Full Text] [Related]
16. Prediction of fetal infection in cases with cytomegalovirus immunoglobulin M in the first trimester of pregnancy: a retrospective cohort.
Leruez-Ville M; Sellier Y; Salomon LJ; Stirnemann JJ; Jacquemard F; Ville Y
Clin Infect Dis; 2013 May; 56(10):1428-35. PubMed ID: 23392397
[TBL] [Abstract][Full Text] [Related]
17. Performance of a cytomegalovirus IgG enzyme immunoassay kit modified to measure avidity.
Prince HE; Lapé-Nixon M; Novak-Weekley SM
Clin Vaccine Immunol; 2014 Jun; 21(6):808-12. PubMed ID: 24671557
[TBL] [Abstract][Full Text] [Related]
18. The combination of specific IgM antibodies and IgG antibodies of low avidity does not always indicate primary infection with cytomegalovirus.
Lumley S; Patel M; Griffiths PD
J Med Virol; 2014 May; 86(5):834-7. PubMed ID: 24395084
[TBL] [Abstract][Full Text] [Related]
19. Improving diagnosis of primary cytomegalovirus infection in pregnant women using immunoblots.
Rajasekariah H; Scott G; Robertson PW; Rawlinson WD
J Med Virol; 2013 Feb; 85(2):315-9. PubMed ID: 23171986
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the diagnostic performance of the IDS-iSYS tests for toxo IgG, toxo IgM and avidity.
Levigne P; Peyron F; Wallon M
Diagn Microbiol Infect Dis; 2016 Oct; 86(2):148-52. PubMed ID: 27450223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
